Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has been assigned an average recommendation of “Moderate Buy” from the seven brokerages that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and two have given a strong buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $18.75.

A number of analysts have weighed in on the stock. TD Cowen upgraded shares of Atara Biotherapeutics to a “strong-buy” rating in a research note on Friday, November 29th. RODMAN&RENSHAW upgraded shares of Atara Biotherapeutics to a “strong-buy” rating in a report on Friday, December 20th. Rodman & Renshaw began coverage on Atara Biotherapeutics in a research note on Friday, December 20th. They set a “buy” rating and a $25.00 target price on the stock. Finally, Canaccord Genuity Group boosted their price target on Atara Biotherapeutics from $13.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th.

Hedge Funds Weigh In On Atara Biotherapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. State Street Corp increased its position in Atara Biotherapeutics by 52.3% during the third quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after acquiring an additional 7,680 shares during the last quarter. FMR LLC increased its position in shares of Atara Biotherapeutics by 41.7% during the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 7,381 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Atara Biotherapeutics in the 2nd quarter worth approximately $79,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Atara Biotherapeutics during the second quarter valued at approximately $53,000. Finally, Vestal Point Capital LP increased its holdings in Atara Biotherapeutics by 11.3% during the third quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock valued at $1,014,000 after buying an additional 12,677 shares during the last quarter. 70.90% of the stock is owned by institutional investors.

Atara Biotherapeutics Stock Down 5.9 %

Shares of ATRA opened at $15.55 on Tuesday. The stock has a market cap of $89.57 million, a P/E ratio of -0.60 and a beta of 0.51. The business’s 50 day moving average price is $12.47 and its 200-day moving average price is $9.89. Atara Biotherapeutics has a 52 week low of $6.50 and a 52 week high of $39.50.

Atara Biotherapeutics (NASDAQ:ATRA) last released its earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) EPS for the quarter, topping the consensus estimate of ($3.77) by $0.84. The company had revenue of $40.19 million during the quarter, compared to the consensus estimate of $23.00 million. During the same period last year, the firm posted ($16.50) earnings per share. On average, equities analysts anticipate that Atara Biotherapeutics will post -12.12 EPS for the current year.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.